Rhythm Pharmaceuticals Inc. (RYTM) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Rhythm Pharmaceuticals Inc. (NASDAQ: RYTM) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $93.44 (+0.94% 1D, market cap $6.37B). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 8/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, RYTM ranks #495 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RYTM carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of 89.7%, and ROIC of -29.6%. By comparison, LGND (Ligand Pharmaceuticals Incorporated) holds a C grade (62/100 RQD, P/E 50.8x, ROIC 3.0%, cap $6.43B) and BLTE (Belite Bio Inc) posts a D- grade (36/100 RQD, P/E N/A, ROIC -15.9%, cap $6.23B). Among the 5-stock peer group, LGND leads on earnings multiple (50.8x) while LGND leads on capital efficiency (3.0% ROIC).
Per RYTM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001649904), Rhythm Pharmaceuticals Inc. generated $189.8M in revenue (+45.8% YoY), -$196.5K in net income, and -$116.6M in free cash flow against $480.2M in total assets and $100.9M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 14.33 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9
20D Institutional Volume Accumulation (±6.5% realized swing band)
Dilution Drag (+1.92% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
While RYTM currently carries a cautious 38/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($96.06) and Max Pain ($98.11) forces dealer call-delta covering toward $128.31.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Rhythm Pharmaceuticals Inc. (RYTM) advanced +0.94% to $93.44, trading at 40% of its 52-week range ($74.5 – $122.2). Stretched risk/reward at current multiples (-30% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance report covering Rhythm Pharmaceuticals Inc. (RYTM) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Rhythm Pharmaceuticals Inc. (RYTM) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Rhythm Pharmaceuticals Inc. (RYTM) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Rhythm Pharmaceuticals Inc. (RYTM) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Rhythm Pharmaceuticals Inc. (RYTM) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Rhythm Pharmaceuticals Inc. (RYTM) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Rhythm Pharmaceuticals Inc. (RYTM) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Rhythm Pharmaceuticals Inc. (RYTM) market action, institutional positioning, and fundamental catalysts.
CAMP4 Therapeutics Corporation (CAMP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CHICAGO, October 21, 2026--William Blair today announced that Alethia Young has initiated coverage of 13 biotechnology companies, marking the next step in the firm’s continued expansion of its biotech offering.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +45.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on RYTM today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for RYTM. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, Rhythm Pharmaceuticals Inc. (RYTM) ranks #495 by composite RQD confidence (38/100, grade D-) and #141 by equity capitalization ($6.37B). Within this direct 5-issuer industry benchmark cohort, LGND leads on earnings valuation at 50.8x trailing P/E, while LGND leads on capital efficiency and profitability with 3.0% ROIC and — gross margin. LGND currently holds the highest overall quantitative score in the immediate peer group at 62/100 (C) compared with RYTM at 38/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| RYTM
ACTIVE
Rhythm Pharmaceuticals Inc. | D- | 38/100 | — | 89.7% | -29.6% | +0.94% | $6.37B | Benchmark Subject |
| LGND Ligand Pharmaceuticals Incorporated | C | 62/100 | 50.8x | — | 3.0% | -4.87% | $6.43B | /lgnd-vs-rytm → |
| BLTE Belite Bio Inc | D- | 36/100 | — | — | -15.9% | -0.69% | $6.23B | /blte-vs-rytm → |
| MANE Veradermics Incorporated | D+ | 55/100 | — | — | -11.9% | -7.27% | $5.84B | /mane-vs-rytm → |
| IONS Ionis Pharmaceuticals Inc. | E | 26/100 | — | 96.0% | -20.9% | -5.24% | $7.23B | /ions-vs-rytm → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Rhythm Pharmaceuticals Inc. (RYTM) reported GAAP revenue of $189.8M (+45.8% vs. FY2024 revenue of $130.1M , and +145.1% cumulative change since FY2023) , GAAP net income of -$196.5K, operating cash flow of -$115.7M, and free cash flow of -$116.6M (-2.4% YoY). On the balance sheet, RYTM closed FY2025 with $480.2M in total assets against $100.9M in total debt (Altman Z-Score: 14.33, Piotroski F-Score: 5/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $189.8M | -$196.5K | -$115.7M | -$116.6M | $480.2M | $100.9M |
| FY2024 (FY) | 2024-12-31 | $130.1M | -$260.6K | -$113.9M | -$113.9M | $392.3M | $108.3M |
| FY2023 (FY) | 2023-12-31 | $77.4M | -$184.7K | -$136.2M | -$139.6M | $3.52B | $824.7M |
As of 2026-11-03, Rhythm Pharmaceuticals Inc. (NASDAQ: RYTM) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $93.44 (+0.94% 1D, market cap $6.37B). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 8/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, RYTM ranks #495 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RYTM carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of 89.7%, and ROIC of -29.6%. By comparison, LGND (Ligand Pharmaceuticals Incorporated) holds a C grade (62/100 RQD, P/E 50.8x, ROIC 3.0%, cap $6.43B) and BLTE (Belite Bio Inc) posts a D- grade (36/100 RQD, P/E N/A, ROIC -15.9%, cap $6.23B). Among the 5-stock peer group, LGND leads on earnings multiple (50.8x) while LGND leads on capital efficiency (3.0% ROIC).
Per RYTM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001649904), Rhythm Pharmaceuticals Inc. generated $189.8M in revenue (+45.8% YoY), -$196.5K in net income, and -$116.6M in free cash flow against $480.2M in total assets and $100.9M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
RYTM last traded at $93.44 (+0.94% on volume of 2,003,985 shares), positioning the stock -2.73% below its 50-day simple moving average ($96.06) and -3.61% below its 200-day simple moving average ($96.94). Across its 52-week range of $74.50 to $122.20, RYTM sits at the 39.7% percentile with a 14-day RSI of 50.0 (NEUTRAL RANGE) and an implied next-earnings move of ±6.5% ($87.37 to $99.51).
Rhythm Pharmaceuticals Inc. (RYTM) earns a live Roarable RQD composite score of 38/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $93.44 (+0.94% 1D, market capitalization $6.37B).
Rhythm Pharmaceuticals Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry. Per the market data, the company reports a gross margin of 89.7%. Per the news wire, its public narrative centers on Prader-Willi and genetically defined obesity therapies. —: specific products, customer segments, and revenue mix.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Rhythm Pharmaceuticals Inc. (RYTM) reported $189.8M in annual revenue (up from $130.1M in FY2024, +45.8% YoY) and -$196.5K in GAAP net income. Over the multi-year SEC filing window from FY2023 ($77.4M revenue, -$184.7K net income) through FY2025, RYTM scaled operating cash flow to -$115.7M and free cash flow to -$116.6M, backed by $480.2M in total assets against $100.9M in total debt.
—: upstream suppliers, downstream customers, contract manufacturers, and sector correlation data. A prospective investor should note that the absence of mapped dependencies means second-order bottlenecks cannot be assessed from these sources.
Real-time company headlines, analyst actions, and sector developments for Rhythm Pharmaceuticals Inc. (RYTM) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering Rhythm Pharmaceuticals Inc. (RYTM) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Rhythm Pharmaceuticals Inc. (RYTM) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Rhythm Pharmaceuticals Inc. (RYTM) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Rhythm Pharmaceuticals Inc. (RYTM) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Rhythm Pharmaceuticals Inc. (RYTM) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Rhythm Pharmaceuticals Inc. (RYTM) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Rhythm Pharmaceuticals Inc. (RYTM) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Rhythm Pharmaceuticals Inc. (RYTM) market action, institutional positioning, and fundamental catalysts.
Long RYTM at $92.57 targeting $122.19. Revenue grew from $77.4M in FY 2023 to $189.8M in FY 2025 and the Altman Z-Score of 14.33 signals a sturdy balance sheet.. Institutional whale score is 8/20 and the risk/reward vs. the $74.50 52-week low is skewed heavily in favor of bulls.
@QuantViper Agree on the RQD 38/100 quality, though with 0.96 beta I'm scaling in with half-size at $92.57 and keeping dry powder in case we test $86.09.
Fading this rally in RYTM at $92.57. Operating income of -$192.0M and FCF of -$116.6M in FY 2025 against ROIC of -29.6% show the business is not yet converting growth into cash.. With a beta of 0.96 and the stock sitting at $92.57 (52-wk range $74.50–$122.20), the easy multiple expansion is already priced in.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your first name and email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).
Your $100,000 Virtual Cash Trading Account is active! Add your mobile number below if you want our #1 Weekly Quant Top Pick plus urgent breaking market alerts & SEC Form 4 CEO cluster-buy flashes sent straight to your phone: